Clinical Trial Update: Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing SYN023 to human rabies immune globulin for post-exposure prophylaxis of rabies has completed. Results were posted on January 16…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• Rabies immune globulin (rabies immune globulin)
• SYN023 (SYN023)

Snippet

Sponsor: Synermore Biologics Co., Ltd. | Conditions: Rabies | Phase 2 | Status: COMPLETED | Results posted: 2026-01-16